Prelude Therapeutics Incorporated
Prelude Therapeutics develops precision oncology medicines, including KAT6A degraders and JAK2V617F mutant selective inhibitors, as well as degrader antibody conjugates for cancer treatment.
8-KSep 10Latest SEC filing, period to Sep 10
Sep 10Latest story
September 2026
August 2026